Skip to main content
Signal8

OCULAR THERAPEUTIX, INC (OCUL)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Ocular Therapeutix, Inc. logo

Ocular Therapeutix, Inc.

NASDAQ:OCULHealthcare
-6.14%$6.19
Mkt Cap$1.36B
Float190.63M
O/S219.62M
VOL452K sh
$ Vol$2.78M
RVOL0.16×
Inst Own94.0%
SI15.1%
Dilution
Ocular Therapeutix, Inc. logoNASDAQ:OCUL$6.19-6.14%
Historical Data
DateOpenHighLowCloseVolume
Nov 9, 20266.256.306.056.11454,091
Nov 6, 20266.536.756.526.591,957,240
Nov 5, 20267.157.246.416.433,130,016
Nov 4, 20267.097.176.837.143,360,665
Nov 3, 20266.826.976.766.822,001,473
Nov 2, 20266.977.036.586.731,883,301
Oct 30, 20267.277.386.926.972,629,771
Oct 29, 20267.367.547.297.312,210,806
Oct 28, 20266.687.346.607.292,854,126
Oct 27, 20266.486.756.426.722,215,307
Oct 26, 20266.506.626.406.471,690,501
Oct 23, 20266.686.686.346.501,855,969
Oct 22, 20266.426.676.396.612,145,011
Oct 21, 20266.696.756.386.482,491,837
Oct 20, 20266.306.786.306.652,617,324
Oct 19, 20267.137.186.006.298,357,920
Oct 16, 20267.387.396.856.872,761,648
Oct 15, 20267.297.467.237.383,252,526
Oct 14, 20267.147.307.077.202,208,787
Oct 13, 20267.557.617.207.243,216,271
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
17
HOLD
2
SELL
0
TOTAL19
Insider Trades
InsiderTypeShares
Anderman Todd profile photoAnderman ToddSale12.0K
Kaiser Peter profile photoKaiser PeterSale10.0K
Heier Jeffrey S. profile photoHeier Jeffrey S.Sale10.9K
Notman Donald profile photoNotman DonaldSale1.1K
Dugel Pravin profile photoDugel PravinWithholding/Transfer50.1K
Dugel Pravin profile photoDugel PravinWithholding/Transfer50.1K
Shareholders
94.0%
Institutional
(262)
2.5%
Insiderⓘ
(17)
3.1%
5%+ Owners
(1)
0.3%
Unattributed (incl. retail)ⓘ
Institutional94.0%
Insider2.5%
5%+ Beneficial3.1%
Unattributed (incl. retail)0.3%
Sources: 13F, Form 4, 13D/13GO/S: 219.6M · as of 31 Jul 2026 · SEC cover page
Insiders & Institutional Holders
About

Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions.

The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis.

In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC.

Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.

Key Metrics
Market Cap$1.36B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership94.02%

based on 219.62M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateJul 25, 2014
Shares Outstanding219.62M
Authorized Shares
Float190.63M
52-Week Range
$6.00$16.44
$6.19(2nd percentile)
Volume
Average Daily Volume2.71M
454.09K today vs 2.71M avg(-83%)

30d Avg

2.71M

60d Avg

3.24M

90d Avg

3.09M

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...